Colorectal cancer prognostic biomarker test
| Reference number | |
| Coordinator | Umeå Biotech Incubator AB |
| Funding from Vinnova | SEK 1 379 075 |
| Project duration | December 2015 - March 2018 |
| Status | Completed |
Important results from the project
The goal of the project was to finalize the development of a biomarker test for patients with colorectal cancer. Development has been very positive. The prototype is finalized and transfer to production will be initiated soon. Prospective clinical study has started and collection of samples is ongoing. HiloProbe AB is formed and is the owner of the product patent. Promising discussions with investors are ongoing. Delays have been encountered with clinical study and CE documentation.
Expected long term effects
During the years that we received support from SWElife we have verified that our product has great clinical value and future successful sales possibility. We have finalized the prototype and will soon start transfer to production, initiated a prospective clinical study, received a Swedish patent, developed market plan, developed a brand platform, developed a finance strategy and have ongoing discussion with investors for continued financing of the development.
Approach and implementation
The project has progressed according to the project plan. Some activities have taken more time than planned. All activities have contributed with important information and knowledge, forming the basis for strategies that we have developed and decisions that we have made. Performing different activities in parallel during project development has proven to be important improving results.